UNITED STATES OF AMERICA —Brain–computer interface developer Precision Neuroscience has completed a $250 million Series D financing round, bringing its total institutional funding to $430 million. The investment round saw co-leadership from Pershing Square Inc., the Ackman Oxman Institute, and an undisclosed life sciences fund, alongside participation from institutional investors including Mubadala Capital, Duquesne Family Office, B Capital, and ARK Invest.
Precision Neuroscience is a neurotechnology firm developing minimally invasive, high-bandwidth brain–computer interface systems designed to treat severe neurological conditions. Founded in 2021, the firm maintains an in-house microelectromechanical systems manufacturing facility in Texas and has secured regulatory clearance for its primary cortical interface device.
The newly injected capital will fund the expansion of clinical trials, support commercialization infrastructure, and accelerate regulatory submissions with health authorities. The commercial trajectory of neural technology is accelerating as private capital moves toward high-channel recording arrays capable of commercial deployment. Expanding clinical trial access across major health systems remains essential for establishing safety baselines and gathering high-resolution neural data required for broader regulatory clearances.
This capital influx highlights rising investor demand for advanced medical technology, placing neurotechnology alongside pharmaceutical and traditional medtech sectors. Health systems and clinical research centers face increasing operational demand to integrate neurosurgical recording platforms, while commercial partnerships with major medical device manufacturers are expected to drive long-term platform integration across hospitals.
For global venture capital and public market investors, the transaction signals strong market conviction in non-destructive, removable neural interfaces. Securing end-to-end supply chain control through proprietary manufacturing facilities offers a strategic blueprint for medical device companies seeking to reduce regulatory and production bottlenecks prior to commercial rollouts.
